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Abstract
Blood pressure (BP) is a heritable trait1 influenced by multiple biological pathways and is 
responsive to environmental stimuli. Over one billion people worldwide have hypertension (BP 
≥140 mm Hg systolic [SBP] or ≥90 mm Hg diastolic [DBP])2. Even small increments in BP are 
associated with increased risk of cardiovascular events3. This genome-wide association study of 
SBP and DBP, which used a multi-stage design in 200,000 individuals of European descent, 
identified 16 novel loci: six of these loci contain genes previously known or suspected to regulate 
BP (GUCY1A3-GUCY1B3; NPR3-C5orf23; ADM; FURIN-FES; GOSR2; GNAS-EDN3); the 
other 10 provide new clues to BP physiology. A genetic risk score based on 29 genome-wide 
significant variants was associated with hypertension, left ventricular wall thickness, stroke, and 
coronary artery disease, but not kidney disease or kidney function. We also observed associations 
with BP in East Asian, South Asian, and African ancestry individuals. Our findings provide new 
insights into the genetics and biology of BP, and suggest novel potential therapeutic pathways for 
cardiovascular disease prevention.
Genetic approaches have advanced the understanding of biological pathways underlying 
inter-individual variation in BP. For example, studies of rare Mendelian BP disorders have 
identified multiple defects in renal sodium handling pathways4. More recently two genome-
wide association studies (GWAS), each of >25,000 individuals of European-ancestry, 
identified 13 loci associated with SBP, DBP, and hypertension5,6. We now report results of a 
new meta-analysis of GWAS data that includes staged follow-up genotyping to identify 
additional BP loci.
Primary analyses evaluated associations between 2.5 million genotyped or imputed single 
nucleotide polymorphisms (SNPs) and SBP and DBP in 69,395 individuals of European 
ancestry from 29 studies (Supplementary Materials Sections 1–3, Supplementary Tables 1–
2). Following GWAS meta-analysis, we conducted a three-stage validation experiment that 
made efficient use of available genotyping resources, to follow up top signals in up to 
133,661 additional individuals of European descent (Supplementary Fig. 1 and 
Supplementary Materials Section 4). Twenty-nine independent SNPs at 28 loci were 
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significantly associated with SBP, DBP, or both in the meta-analysis combining discovery 
and follow up data (Fig. 1, Table 1, Supplementary Figs 2–3, Supplementary Tables 3–5). 
All 29 SNPs attained association P <5×10−9, an order of magnitude beyond the standard 
genome-wide significance level for a single stage experiment (Table 1).
Sixteen of these 29 associations were novel (Table 1). Two associations were near the 
FURIN and GOSR2 genes; prior targeted analyses of variants in these genes suggested they 
may be BP loci7,8. At the CACNB2 locus we validated association for a previously reported6 
SNP rs4373814 and detected a novel independent association for rs1813353 (pairwise r2 
=0.015 in HapMap CEU). Of our 13 previously reported associations5,6, only the association 
at PLCD3 was not supported by the current results (Supplementary Table 4). Some of the 
associations are in or near genes involved in pathways known to influence BP (NPR3, 
GUCY1A3-GUCY1B3, ADM, GNAS-EDN3, NPPA-NPPB, and CYP17A1; Supplementary 
Fig. 4). Twenty-two of the 28 loci did not contain genes that were a priori strong biological 
candidates.
As expected from prior BP GWAS results, the effects of the novel variants on SBP and DBP 
were small (Fig. 1 and Table 1). For all variants, the observed directions of effects were 
concordant for SBP, DBP, and hypertension (Fig. 1, Table 1, Supplementary Fig. 3). Among 
the genes at the genome-wide significant loci, only CYP17A1, previously implicated in 
Mendelian congenital adrenal hyperplasia and hypertension, is known to harbour rare 
variants that have large effects on BP9.
We performed several analyses to identify potential causal alleles and mechanisms. First, we 
looked up the 29 genome-wide significant index SNPs and their close proxies (r2>0.8) 
among cis-acting expression SNP (eSNP) results from multiple tissues (Supplementary 
Materials Section 5). For 13/29 index SNPs, we found association between nearby eSNP 
variants and expression level of at least one gene transcript (10−4 > p > 10−51, 
Supplementary Table 6). In 5 cases, the index BP SNP and the best eSNP from a genome-
wide survey were identical, highlighting potential mediators of the SNP-BP associations.
Second, because changes in protein sequence are strong a priori candidates to be functional, 
we sought non-synonymous coding SNPs that were in high LD (r2 >0.8) with the 29 index 
SNPs. We identified such SNPsat 8 loci (Table 1, Supplementary Materials Section 6, 
Supplementary Table 7). In addition we performed analyses testing for differences in genetic 
effect according to body mass index (BMI) or sex, and analyses of copy number variants, 
pathway enrichment, and metabolomic data, but we did not find any statistically significant 
results (Supplementary Materials Sections 7–9, Supplementary Tables 8–10).
We evaluated whether the BP variants we identified in Europeans were associated with BP 
in individuals of East Asian (N=29,719), South Asian (N=23,977), and African (N=19,775) 
ancestries (Table 1, Supplementary Tables 11–13). We found significant associations in 
individuals of East Asian ancestry for SNPs at 9 loci and in individuals of South Asian 
ancestry for SNPs at 6 loci; some have been reported previously (Supplementary Tables 12 
and 15). The lack of significant association for individual SNPs may reflect small sample 
sizes, differences in allele frequencies or LD patterns, imprecise imputation for some 
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ancestries using existing reference samples, or a genuinely different underlying genetic 
architecture. Because of limited power to detect effects of individual variants in the smaller 
non-European samples, we created genetic risk scores for SBP and DBP incorporating all 29 
BP variants weighted according to effect sizes observed in the European samples. In each 
non-European ancestry group, risk scores were strongly associated with SBP (P=1.1×10−40 
in East Asian, P=2.9×10−13 in South Asian, P=9.8×10−4 in African ancestry individuals) 
and DBP (P=2.9×10−48, P=9.5×10−15, and P=5.3×10−5, respectively; Supplementary Table 
13).
We also created a genetic risk score to assess association of the variants in aggregate with 
hypertension and with clinical measures of hypertensive complications including left 
ventricular mass, left ventricular wall thickness, incident heart failure, incident and prevalent 
stroke, prevalent coronary artery disease (CAD), kidney disease, and measures of kidney 
function, using results from other GWAS consortia (Table 2, Supplementary Materials 
Sections 10–11, Supplementary Table 14). The risk score was weighted using the average of 
SBP and DBP effects for the 29 SNPs. In an independent sample of 23,294 women10, an 
increase of 1 standard deviation in the genetic risk score was associated with a 21% increase 
in the odds of hypertension (95% CI 19%–28%; Table 2, Supplementary Table 14). Among 
individuals in the top decile of the risk score, the prevalence of hypertension was 29% 
compared with 16% in the bottom decile (odds ratio 2.09, 95% CI 1.86–2.36). Similar 
results were observed in an independent hypertension case-control sample (Table 2). In our 
study, individuals in the top compared to bottom quintiles of genetic risk score differed by 
4.6 mm Hg SBP and 3.0 mm Hg DBP, differences that approach population-averaged BP 
treatment effects for a single antihypertensive agent11. Epidemiologic data have shown that 
differences in SBP and DBP of this magnitude, across the population range of BP, are 
associated with an increase in cardiovascular disease risk3. Consistent with this and in line 
with findings from randomized trials of BP-lowering medication in hypertensive 
patients12,13, the genetic risk score was positively associated with left ventricular wall 
thickness (P=6.0×10−6), occurrence of stroke (P=3.3×10−5) and CAD (P=8.1×10−29). The 
same genetic risk score was not, however, significantly associated with chronic kidney 
disease or measures of kidney function, even though these renal outcomes were available in 
a similar sample size as for the other outcomes (Table 2). The absence of association with 
kidney phenotypes could be explained by a weaker causal relation of BP with kidney 
phenotypes than with CAD and stroke. This finding is consistent with the mismatch between 
observational data that show a positive association of BP with kidney disease, and clinical 
trial data that show inconsistent evidence of benefit of BP lowering on kidney disease 
prevention in patients with hypertension14. Thus, several lines of evidence converge to 
suggest that BP elevation may in part be a consequence rather than a cause of sub-clinical 
kidney disease.
Our discovery meta-analysis (Supplementary Fig. 2) suggests an excess of modestly 
significant (10−5 <P <10−2) associations likely arising from common BP variants of small 
effect. By dividing our principal GWAS dataset into non-overlapping discovery (N≈56,000) 
and validation (N≈14,000) subsets, we found robust evidence for the existence of such 
undetected common variants (Supplementary Fig. 5, Supplementary Materials Section 12). 
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We estimate15 that there are 116 (95% CI 57–174) independent BP variants with effect sizes 
similar to those reported here, which collectively explain ≈2.2% of the phenotypic variance 
for SBP and DBP, compared with 0.9% explained by the 29 associations discovered thus far 
(Supplementary Fig. 6, Supplementary Materials Section 13).
Most of the 28 BP loci harbour multiple genes (Supplementary Table 15, Supplementary 
Fig. 4), and although substantial research is required to identify the specific genes and 
variants responsible for these associations, several loci contain highly plausible biological 
candidates. The NPPA and NPPB genes at the MTHFR-NPPB locus encode precursors for 
atrial- and B-type natriuretic peptides (ANP, BNP), and previous work has identified SNPs, 
modestly correlated with our index SNP at this locus, that are associated with plasma ANP, 
BNP, and BP16. We found the index SNP at this locus was associated with opposite effects 
on BP and on ANP/BNP levels, consistent with a model in which the variants act through 
increased ANP/BNP production to lower BP16 (Supplementary Materials Section 14).
Two other loci identified in the current study harbour genes involved in natriuretic peptide 
and related nitric oxide signalling pathways,17,18 both of which act to regulate cyclic 
guanosine monophosphate (cGMP). The first locus contains NPR3, which encodes the 
natriuretic peptide clearance receptor (NPR-C). NPR3 knockout mice exhibit reduced 
clearance of circulating natriuretic peptides and lower BP19. The second locus includes 
GUCY1A3 and GUCY1B3, encoding the alpha and beta subunits of soluble guanylatecyclase 
(sGC); knockout of either gene in murine models results in hypertension20.
Another locus contains ADM, encoding adrenomedullin, which has natriuretic, vasodilatory, 
and BP-lowering properties21. At the GNAS-EDN3 locus, ZNF831 is closest to the index 
SNP, but GNAS and EDN3 are two nearby compelling biological candidates (Supplementary 
Fig. 4, Supplementary Table 15).
We identified two loci with plausible connections to BP via genes implicated in renal 
physiology or kidney disease. At the first locus, SLC4A7 is an electro-neutral sodium 
bicarbonate co-transporter expressed in the nephron and in vascular smooth muscle22. At the 
second locus, PLCE1 (phospholipase-C-epsilon-1 isoform) is important for normal podocyte 
development in the glomerulus; sequence variation in PLCE1 has been implicated in 
familial nephrotic syndromes and end-stage kidney disease23.
Missense variants in two genes involved in metal ion transport were associated with BP in 
our study. The first encodes a His/Asp change at amino acid 63 (H63D) in HFE and is a low 
penetrance allele for hereditary hemochromatosis24. The second is an Ala/Thr 
polymorphism located in exon 7 of SLC39A8, which encodes a zinc transporter that also 
transports cadmium and manganese25. The same allele of SLC39A8 associated with BP in 
our study has recently been associated with high-density lipoprotein (HDL) cholesterol 
levels26 and BMI27 (Supplementary Table 15).
In conclusion, we have shown that 29 independent genetic variants influence BP in people 
of European ancestry. The variants reside in 28 loci, 16 of which were novel, and we 
confirmed association of several of them in individuals of non-European ancestry. A risk 
score derived from the 29 variants was significantly associated with BP-related organ 
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damage and clinical cardiovascular disease, but not kidney disease. These loci improve our 
understanding of the genetic architecture of BP, provide new biological insights into BP 
control and may identify novel targets for the treatment of hypertension and the prevention 
of cardiovascular disease.
Methods summary
Supplementary Materials provide complete methods and include the following sections: 
study recruitment and phenotyping, adjustment for antihypertensive medications, 
genotyping, data quality control, genotype imputation, within-cohort association analyses, 
meta-analyses of discovery and validation stages, stratified analyses by sex and BMI, 
identification of eSNPs and nsSNPs, metabolomic and lipidomic analyses, CNV analyses, 
pathway analyses, analyses for non-European ancestries, association of a risk score with 
hypertension and cardiovascular disease, estimation of numbers of undiscovered variants, 
measurement of natriuretic peptides, and brief literature reviews and GWAS database 
lookups of all validated BP loci.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Genome-wide –log10 P-value plots and effects for significant loci.
Genome-wide –log10 P-value plots are shown for systolic (SBP: panel a) and diastolic 
(DBP: panel b). SNPs within loci reaching genome-wide significance are labeled in red for 
SBP and blue for DBP (±2.5Mb of lowest P-value) and lowest P-values in the initial 
genome-wide analysis as well as the results of analysis including validation data are labeled 
separately. The lowest P-values in the initial GWAS are denoted as an X. The range of 
different sample sizes in the final meta-analysis including the validation data are indicated 
as: circle (96–140k), triangle (>140–180k), and diamond (>180–220k). SNPs near 
unconfirmed loci are in black. The horizontal dotted line is P=2.5 × 10−8. Panel c shows the 
effect size estimates and 95% confidence bars per BP-increasing allele of the 29 significant 
variants for SBP (red) and DBP (blue). Effect sizes are expressed in mmHg/allele. GUCY = 
GUCY1A3-GUCY1B3.
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